ArticleJournal of musculoskeletal & neuronal interactions2026
HOXA7 Impairs Osteogenic Differentiation via p38/JNK Signaling: Implications for Osteoporosis.
Article in Journal of musculoskeletal & neuronal interactions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo elucidate the role and mechanism of HOXA7 in osteoporosis (OP), with the goal of informing future research directions in OP.
methodsWe assessed HOXA7 gene and protein expression; the effect of HOXA7 on osteogenic differentiation in human bone marrow-derived mesenchymal stem cells (hBMSCs); and proliferation, apoptosis, and autophagy in MC3T3-E1 cells. We also evaluated p38 MAPK/JNK pathway-associated proteins in hBMSCs and MC3T3-E1 cells. Cells were transfected with si-HOXA7 and cultured with or without the JNK inhibitor SP600125 or the p38 inhibitor SB203580, after which cell viability, apoptosis, and autophagy were re-assessed.
resultsHOXA7 overexpression inhibited osteogenic differentiation of hBMSCs, reduced OPG, OPN, and RUNX2 expression in hBMSCs, and decreased proliferation while promoting apoptosis in MC3T3-E1 cells. In vitro, HOXA7 modulated autophagy markers in MC3T3-E1 cells. Phosphorylated JNK and p38 (p-JNK, p-p38) were increased in hBMSCs following osteogenic induction, whereas HOXA7 upregulation significantly suppressed p-JNK and p-p38 in MC3T3-E1 cells. SP600125 and SB203580 attenuated the effects of HOXA7 silencing on proliferation, apoptosis, and autophagy in MC3T3-E1 cells.
conclusionHOXA7 reduces osteogenesis and osteoblast proliferation and promotes osteoblast apoptosis via the p38 MAPK/JNK pathway, suggesting potential therapeutic avenues against OP.
Indexed as
Identifiers
41764761PMC12952508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.